Teva to market generic version of AstraZeneca's antipsychotic agent Seroquel tablets

NewsGuard 100/100 Score
Sep 26 2009

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 1, 2008 decision by the District Court to grant AstraZeneca’s motion for summary judgment of no inequitable conduct related to U.S. Patent No. 4,879,288. As a result of today’s decision, Teva expects to market its generic version of AstraZeneca's antipsychotic agent Seroquel® (Quetiapine Fumarate) Tablets no later than March 2012, when the patent is otherwise set to expire.

Source:

Teva Pharmaceutical Industries Ltd.

Posted in: Medical Patent News | Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

Study shows antipsychotic drugs increase health risks in dementia patients
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals
Lancet Commission predicts sharp increase in global prostate cancer cases
Croatian sea fennel may contain a treasure trove of preservative and anti-aging metabolites
LabVantage celebrates customer success with record number of software deployments in FY 2024
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Study highlights global fertility decline and its implications for the future

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Common HIV drugs linked to reduced Alzheimer's disease risk